Table 4.
Analysis of risk factors associated with mortality at 6 months
| Risk factors | Control (n = 82) | Death at 6 months (n = 15) | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | p value | OR | 95% CI | p value | |||
| Male gender (%) | 65 (79.3) | 10 (66.7) | 1.9 | 0.6–6.3 | 0.319 | |||
| Age (mean±SD), years | 58.8±11.8 | 62.6±15.1 | 0.273 | |||||
| Etiology eradication (%) | 47/67 (70.1) | 7/11 (63.6) | 1.3 | 0.4–5.1 | 0.729 | |||
| Child-Pugh B/C (%) | 16/72 (22.2) | 7/13 (53.8) | 4.1 | 1.2–13.9 | 0.037 | 2.7 | 0.4–20.3 | 0.336 |
| MELD-Na, median (IQR) | 11.0 (8.5–14.0) | 15.0 (10.0–22.0) | 0.016 | 1.3 | 1.1–1.6 | 0.016 | ||
| PVT (%) | 15 (18.3) | 7 (46.7) | 3.9 | 1.2–12.4 | 0.038 | 10.5 | 1.4–79.4 | 0.023 |
| HCC (%) | 6 (7.3) | 3 (20.0) | 3.2 | 0.7–14.4 | 0.142 | |||
| NSBBs (%) | 52 (63.4) | 10/14 (71.4) | 1.4 | 0.4–5.0 | 0.764 | |||
| Nr.EBL sessions (mean±SD) | 4.2±2.0 | 3.7±1.9 | 0.363 | |||||
| Incomplete VE (%) | 26 (31.7) | 12 (80.0) | 0.1 | 0.03–0.5 | < 0.001 | 23.4 | 2.6–211.9 | 0.005 |
| Severe PHG (%) | 32 (39.0) | 7 (46.7) | 1.4 | 0.5–4.1 | 0.579 | |||
| Pandemic group (%) | 36 (43.9) | 8 (53.3) | 1.5 | 0.5–4.4 | 0.500 | |||
SD, standard deviation; MELD, model of end-stage liver disease; IQR, interquartile range; PVT, portal vein thrombosis; HCC, hepatocellular carcinoma; NSBBs, nonselective β-blockers; INR, EBL, endoscopic band ligation; VE, variceal eradication; PHG, portal hypertensive gastropathy.